Tempus AI, Inc. reported total revenue of $1.272 billion for the year ended December 31, 2025, marking an 83% increase compared to the $693.4 million reported for the year ended December 31, 2024. This growth was primarily driven by a 111% increase in Diagnostics revenue, which reached $955.4 million, and a 31% increase in Data and applications revenue, totaling $316.4 million. Despite the significant revenue growth, the company reported a net loss of $245 million for 2025, a substantial decrease from the $705.8 million net loss in 2024. The company's adjusted EBITDA improved to $(7.4) million in 2025 from $(104.7) million in 2024.
The Diagnostics revenue increase was attributed to a rise in the number of oncology tests and the addition of hereditary tests following the acquisition of Ambry Genetics Corporation in February 2025. Oncology test volume increased from approximately 270,800 in 2024 to 340,500 in 2025, with average revenue per test rising from $1,510 to $1,600. The Ambry acquisition contributed approximately 460,500 hereditary tests. Data and applications revenue growth was primarily driven by increased demand for Insights products. As of December 31, 2025, the company had contracts with a Remaining Total Contract Value (TCV) of more than $1.1 billion, which includes approximately $300 million in additional potential future contractual opt-ins.
Key operational developments included the acquisition of Ambry Genetics Corporation for $375 million in cash and 4,843,136 shares of Class A common stock, and the acquisition of Paige.AI, Inc. for $3 million in cash and 1,256,977 shares of Class A common stock. These acquisitions expanded Tempus's capabilities in hereditary cancer screening and digital pathology, respectively. The company also entered into a series of agreements with AstraZeneca AB and Pathos for the development of a foundation large multimodal model in the field of oncology. As of December 31, 2025, the company had more than 3,800 employees, with 1,232 in technical and research and development roles.
Looking ahead, Tempus AI intends to continue investing in research and development, technology, and sales and marketing to drive further growth. The company expects to expand its Platform into new disease areas and develop algorithmic diagnostics. However, the company acknowledges that its future performance is subject to various risks, including competition, regulatory changes, and the need to secure adequate reimbursement for its tests. The company also announced that Ryan Fukushima was promoted to Chief Executive Officer, Data, and Tom Schoenherr was appointed Chief Executive Officer, Diagnostics, effective February 20, 2026.
About Tempus AI, Inc.
Tempus AI is a healthcare technology company specializing in precision medicine through Intelligent Diagnostics. It combines AI, genomic, clinical, and imaging data to develop personalized, accurate laboratory tests across oncology, neuropsychiatry, cardiology, and infectious diseases. Its platform integrates vast multimodal datasets, enabling data-driven therapy decisions, clinical trial matching, and drug discovery, serving healthcare providers, researchers, and life sciences companies worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.